Clinical Trial Update: A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation [Phase 1]

View source ↗

Summary

Phase 1 study comparing the relative oral bioavailability of JNJ-63623872 formulated as oral concept formulations versus the current tablet formulation for Infl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection

Drugs mentioned

• JNJ-63623872

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Influenza A Virus | Phase 1 | Status: COMPLETED